SCHEMBL6543019

SCHEMBL6543019

COc1cc(C=NO)cc(-c2cc3c(cc2C)C(C)(C)CCC3(C)C)c1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 4/20 0.41
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
HTT P42858 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP1A2 P05177 3/20 0.38
CYP3A4 P08684 3/20 0.38
CYP2C19 P33261 3/20 0.38
PKM P14618 2/20 0.38
MAPK1 P28482 1/20 0.38
MAPT P10636 4/20 0.37
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSP90AA1 P07900 1/20 0.36
XBP1 P17861 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
RARB P10826 1/20 0.36
RARG P13631 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6543012 1.00 RXRA (0.41) RXRAALDH1A1MEN1KMT2AHTT
SCHEMBL6542912 0.87 RXRA (0.40) RXRAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6542908 0.87 RXRA (0.40) RXRAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6541649 0.84 RXRA (0.46) RXRAALDH1A1MEN1KMT2AHPGD
SCHEMBL6541656 0.84 RXRA (0.46) RXRAALDH1A1MEN1KMT2AHPGD
SCHEMBL5491326 0.84 RXRA (0.43) RXRAALDH1A1KMT2AHPGDMAPK1
SCHEMBL22824610 0.80 ALDH1A1 (0.54) ALDH1A1MEN1KMT2AHTTHPGD
SCHEMBL6542749 0.79 RXRA (0.36) RXRAMEN1KMT2ARARBRARG
SCHEMBL6542751 0.79 RXRA (0.36) RXRAMEN1KMT2ARARBRARG
SCHEMBL6541488 0.78 RXRA (0.52) RXRAALDH1A1MEN1KMT2ARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421061-A4 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA INCYTE SAN DIEGO INC (US) 2004-12-22 EP disclosed
EP-1421061-A1 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA Incyte San Diego Incorporated (US) 2004-05-26 EP disclosed
US-20030083357-A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia ORTHO MCNEIL PHARMACEUTICAL INC. 2003-05-01 US disclosed
WO-2003016267-A1 OXIME DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA AND HYPERCHOLESTEREMIA INCYTE SAN DIEGO INCORPORATED (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083357-A1 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia OAT, CPT1A, CYP27A1 RXRA 793/4885ALDH1A1 643/4885MEN1 1312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.